Amarex logo

Tube with COVID- 19 positive blood sample - COVID-19 Clinical Product Development Services | Amarex

COVID-19

An entirely new therapeutic area has emerged because of COVID-19, and Amarex is proud to help in the fight against the pandemic by offering accelerated COVID-19 clinical product development services. Since the outset of this global public health crisis, our staff have worked passionately and tirelessly to get diagnostics, devices, drugs and vaccines to patients fast.

We are experts at streamlining regulatory and clinical trial testing services, and we continue to apply additional resources to rush timelines for all COVID-19 projects.

Our Experience:

  • 20+ clinical projects
  • Product types: Four devices/diagnostics, five drug therapies (NCEs, botanicals, biologics, cell therapies and gene therapies), three biologic therapies and two vaccines
  • Clinical trials: Three (Phase I and Phase II), two sites, 270+ patients; proof of concept through FDA marketing approval
  • Regulatory services: Multiple approved compassionate use, emergency use, EUA, clinical trial agreement, pre-IND meeting, eIND, fast track designation and expanded access applications
  • Projects in the U.S., UK, Canada, Europe, Asia and South America
  • Full-scope and targeted-scope projects
  • Amarex client COVID-19 market approvals: One 510(k)
  • Businesspeople in Amarex corporate building - Resources | Amarex

    Resources

    Find up-to-date resources from our scientists, researchers and lead team members.
  • Amarex CEO Kazem Kazempour with staff - Leadership | Amarex

    Leadership

    Meet our leadership team and learn more about their expertise and commitment to advancing clinical product development.

Contact Us

Book a meeting or send us a message to talk to one of our experts.